Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2022-12-22 00:00:00 ET · period of report 2022-12-21 · accession 0001567619-22-021958 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-22 | 2022-12-21 | FDMT | Moretti August J | CFO | M - OptEx | $9.41 | +3,000 | 6,595 | +83% | +$28.2K |
| D | 2022-12-22 | 2022-12-21 | FDMT | Moretti August J | CFO | M - OptEx | $0.00 | -3,000 | 220.1K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-21 | M | A | 3,000 | $9.41 | 6,595 | D | — | — | (F1) Reflects 1,595 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Rule 16b-3. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-12-21 | M | D | 3,000 | $0.00 | 220,060 | D | $9.41 · — to 2029-03-19 | 3,000 Common Stock | (F2) 25% of the shares subject to the option vest on the first anniversary measured from January 7, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |